Discover how $PTX PTX-100 treatment is breaking new ground in targeted therapies, in our recent company profile and interview with CEO James McDonnell and Proactive Australia #biotech journalist Jonathan Jackson. Learn more 👉 ap1.hubs.ly/y04slQ0 #CancerTherapies #CTCL #PTX100

Jonathon Davidson HotCopper & $PTX CEO James McDonnell discuss the company’s progress with PTX-100, a first-in-class therapy targeting the RAS pathway in cancer. Watch now 👉 ap1.hubs.ly/y056X70 🔗 Stay up-to-date: ap1.hubs.ly/y0576Y0 #Biotech #CancerTherapies

Prescient Therapeutics $PTX CEO James McDonnell discusses the outstanding Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’. Watch now 👉 ap1.hubs.ly/y065Xm0 #CellTherapies #CancerTreatment #Biotech

Special Report 📣Prescient Therapeutics $PTX is focussed on developing new therapies for cancers of unmet need - aggressive diseases that can devastate lives and for which treatment options remain limited. Read more 👉 ap1.hubs.ly/y065n60 #Biotech #CancerTreatments

$PTX CEO James McDonnell chats with Stockhead’s Senior Health and Biotech journalist Nadine McGrath, on the “Vital Signs" podcast. Listen now 👉 ap1.hubs.ly/y069ML0 🔗 Stay up-to-date on Prescient’s news: ap1.hubs.ly/y069Pb0 #Biotech #Health #CellTherapies

$PTX is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma. Read more 👉 ap1.hubs.ly/y06jlz0 🔗 Stay up-to-date on PTX news: ap1.hubs.ly/y06jwk0 #Biotech #Health

One in five people will get cancer in their lifetime - Prescient Therapeutics $PTX is working to improve the lives of people suffering from cancers of unmet need. Read more 👉 ap1.hubs.ly/y06jx10 🔗 Stay up-to-date on PTX: ap1.hubs.ly/y06jlB0 #Health #CancerTreatments

$PTX CEO James McDonnell chats with Stockhead’s Tylah Tully to discuss the promising PTX-100 Phase 1b trial results, and how the company is working to improve the lives of people suffering from cancers of unmet need. Watch now 👉 ap1.hubs.ly/y06rN40 #Biotech #Health

Join Prescient Therapeutics (ASX: PTX) CEO James McDonnell at the Twilight Investor Briefing hosted by Monsoon Communications this Wednesday, 9th July in Melbourne CBD. 🔗 RSVP now: ap1.hubs.ly/y06rQF0 #Biotech #Health

Special Report 📣 With a new leadership team and fast-track designation from the US Food and Drug Administration (FDA), clinical-stage oncology company $PTX is laser focused on development of lead compound PTX-100. Read more👉 ap1.hubs.ly/y06BQX0 #Health #Biotech

🎧Small Caps Jess Fertig & $PTX CEO James McDonnell discuss the promising PTX-100 Phase 1b trial results & the designations received from the FDA which could allow Prescient to head toward a US$1.8bn market after Phase 2. Listen now 👉 ap1.hubs.ly/y06BQ60 #Biotech #Health

$PTX announces that the first U.S. Site Initiation Visit has been completed. View 👉 ap1.hubs.ly/y078lt0 This marks a significant milestone in the progress of the Phase 2a trial for PTX-100 for patients suffering with refractory/relapsed Cutaneous T Cell Lymphoma. #Biotech

$PTX CEO James McDonnell chats with Stockhead Tylah Tully to discuss the company’s major milestone with the initiation of its first U.S. site for the Phase 2a trial of PTX-100. Watch now 👉 ap1.hubs.ly/y07n1N0 #Health #Biotech #CancerTreatments

Prescient Therapeutics $PTX has announced the completion of its first U.S. site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). Learn more 👉 ap1.hubs.ly/y07zyV0 #Biotech #Health #CancerTherapies

Prescient Therapeutics $PTX CEO James McDonnell discusses the outstanding Phase 1b results including the 64% tumor halt or reduction for a cancer considered a ‘death sentence’. Watch now 👉 ap1.hubs.ly/y07zCt0 #CellTherapies #CancerTreatment #Biotech

It’s no secret that the rate of cancer both in Australia and overseas appears to be increasing - $PTX is working to improve the lives of people suffering from cancers of unmet need. Learn more 👉 ap1.hubs.ly/y07PqR0 🔗 Stay up-to-date on PTX: ap1.hubs.ly/y07Pfj0 #Health

Gain insights on Prescient’s advanced cancer drug PTX-100, which is in its all-important Phase 2 clinical trials, & working to improve the lives of people suffering from cancers of unmet need👉 ap1.hubs.ly/y07XPR0 🔗 Receive updates on $PTX: ap1.hubs.ly/y07XRw0 #Biotech

Special Report📣 $PTX has entered a critical stage where clinical data, regulatory support & commercial potential begin to converge in a defining moment for a biotech company aiming to bring a new therapy to market. Read more The Australian👉ap1.hubs.ly/y082480 #Health #Biotech

Prescient Therapeutics $PTX is pleased to provide its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the June 2025 quarter. View the announcement 👉 ap1.hubs.ly/y087Vt0 #Biotech #Health #CancerTherapies #CancerTreatment

Special Report 📣 $PTX has raised $3m in a placement to sophisticated and professional investors following a $6.8m SPP for a total $9.8m to advance its pioneering cancer treatment therapy. Read more 👉 ap1.hubs.ly/y08gNc0 #Biotech #Health